Global Generic Injectables Market Expected to Reach USD 99.2 Billion by 2033 - IMARC Group

November 20, 2024 | Healthcare

Global Generic Injectables Market Statistics, Outlook and Regional Analysis 2025-2033

The global generic injectables market size was valued at USD 51.0 Billion in 2024, and it is expected to reach USD 99.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.88% from 2025 to 2033.

Generic Injectables Market

To get more information on this market, Request Sample

The market is witnessing substantial growth for injectable devices, which is driven by technological advancements, rising investment in healthcare innovations, and increased demand for generic formulations. In contrast, companies are focusing on expanding their portfolios to address a broader range of medical needs, thereby emphasizing affordability and accessibility. On the contrary, manufacturers are innovating with new concentrations and formulations to meet varied therapeutic requirements. For instance, in January 2024, Piramal Critical Care (PCC) launched a 10mg/10mL (1 mg/mL) concentration of zinc sulfate, which is enhancing its generic injectables lineup. Therefore, these developments underscore the commitment to diversifying injectable solutions, enabling healthcare providers to offer tailored treatments for better patient outcomes. Meanwhile, the trend towards the commercialization of generic injectable solutions is gaining traction, thereby reinforcing the competitive landscape. For example, in January 2024, Milla Pharmaceuticals Inc. took a significant step by commercializing its Supplemental Abbreviated New Drug Application (sANDA) for a generic version of sodium acetate injection. This product is fundamental for formulating specific intravenous fluids when conventional electrolyte or nutrient solutions are inadequate. Hence, these advancements are important as they facilitate cost-effective treatment alternatives and strengthen the global supply chain of essential drugs, supporting healthcare institutions in managing patient care more efficiently.

Moreover, the introduction of novel injectable products is also accompanied by increased regulatory approvals, facilitating market penetration across various regions. In contrast, companies are leveraging these opportunities to enhance their product reach and support treatment accessibility. The global focus on generic injectables aligns with the aim to provide safe, affordable healthcare solutions in the face of rising chronic disease prevalence and an aging population. In July 2024, Sandoz made headlines by launching Pyzchiva (ustekinumab) across Europe, a significant development in the generic injectables sector. Pyzchiva, developed as a biosimilar by Samsung Bioepis, marks the first ustekinumab biosimilar in the region. This milestone not only broadens Sandoz's immunology portfolio but also promotes wider access to effective treatments for chronic inflammatory diseases. Overall, such region-specific launches underline the strategic efforts by key players to cater to localized market demands and set a precedent for future innovations in the injectable drugs industry.

Global Generic Injectables Market Statistics, By Region

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia, Latin America, and the Middle East and Africa. According to the report, North America dominates the generic injectables market due to its advanced healthcare infrastructure, robust regulatory framework, and significant investments in research and development.

North America Generic Injectables Market Trends:

North America is the dominating region in the market due to its advanced healthcare infrastructure and significant investments in research and development. In January 2024, Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd. focused on developing immunology, oncology, and critical care therapies, announced that its Biologics License Application (BLA) for DMB-3115, a proposed biosimilar to the blockbuster drug STELARA, had been accepted by the U.S. FDA. Thus, presence of leading pharmaceutical companies and initiatives promoting affordable healthcare solutions further bolster North America’s dominant position in the market.

Europe Generic Injectables Market Trends:

Europe is seeing growth in the generic injectables market due to increasing healthcare cost-containment efforts and favorable government policies. In addition, Germany, known for its robust pharmaceutical sector, exemplifies this with initiatives promoting the use of generics. This trend is supported by strong healthcare infrastructure and collaborations between pharmaceutical companies to develop biosimilars, thereby enhancing the accessibility of critical injectable treatments across the region.

Asia Generic Injectables Market Trends:

The region is experiencing rapid expansion in the generic injectables market, which is driven by rising healthcare demands and cost-effective manufacturing. India, as a major player, continues to lead with its large-scale production capabilities and extensive R&D investments. Furthermore, the region’s focus on affordable healthcare solutions and export opportunities contributes to its growth, thereby appealing to global and local markets with competitive pricing.

Latin America Generic Injectables Market Trends:

In Latin America, the injectables market is advancing due to the increasing need for accessible treatment options amidst economic constraints. In contrast, Brazil exemplifies this trend with government-backed initiatives to support local production and reduce reliance on imported medicines. The region's investments in local manufacturing facilities and growing partnerships with international pharmaceutical firms ensure the availability of generic injectables to meet public health needs.

Middle East and Africa Generic Injectables Market Trends:

The Middle East and Africa are witnessing gradual growth in the generic injectables industry as countries like South Africa invest in expanding healthcare services and improving affordability. Also, the trend is fueled by regional efforts to boost local pharmaceutical production and adapt to rising chronic disease rates. International collaborations and supportive regulations are enhancing the distribution and development of cost-effective injectables in these markets.

Top Companies Leading in the Generic Injectables Industry

Some of the leading generic injectables market companies include Baxter International Inc., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Pfizer Inc., Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.), Sandoz International GmbH (Novartis International AG), and Sanofi S.A., among many others. In April 2024, Baxter International introduced five novel generic injectables that feature ready-to-use formulations to help support patient safety. Apart from this, these advancements enhance patient compliance and provide a competitive edge to manufacturers.

Global Generic Injectables Market Segmentation Coverage

On the basis of the therapeutic area, the market has been bifurcated into oncology, anaesthesia, anti-infectives, parenteral nutrition, and cardiovascular, wherein oncology represents the most preferred segment. Oncology represents a significant segment in the market due to the high prevalence and the increasing incidence of cancer worldwide, which drives the demand for cost-effective treatment options.
Based on the container, the market is categorized into vials, ampoules, premix, and prefilled syringes, amongst which vials dominate the market. Vials are a preferred packaging format for a wide range of injectable medications, including antibiotics, vaccines, and oncology drugs, because they offer a stable and secure means of storing and administering these drugs.
On the basis of the distribution channel, the market has been divided into hospitals and retail pharmacy, wherein hospitals represent the most preferred segment. Hospitals rely heavily on injectable medications for their rapid onset of action and high bioavailability, making them essential for emergency care, anesthesia, oncology, and critical care.

Report Features	Details
Market Size in 2024	USD 51.0 Billion
Market Forecast in 2033	USD 99.2 Billion
Market Growth Rate 2025-2033	6.88%
Units	Billion USD
Scope of the Report	Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: Therapeutic Area Container Distribution Channel Region
Therapeutic Areas Covered	Oncology, Anaesthesia, Anti-infectives, Parenteral Nutrition, Cardiovascular
Containers Covered	Vials, Ampoules, Premix, Prefilled Syringes
Distribution Channels Covered	Hospitals, Retail Pharmacy
Regions Covered	Europe, North America, Asia, Latin America, Middle East and Africa
Companies Covered	Baxter International Inc., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Pfizer Inc., Sagent Pharmaceuticals Inc. (Nichi-Iko Pharmaceutical Co. Ltd.), Sandoz International GmbH (Novartis International AG), Sanofi S.A., etc.
Customization Scope	10% Free Customization
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Browse IMARC Related Reports on Generic Injectables Market:

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Generic Injectables Market Expected to Reach USD 99.2 Billion by 2033 - IMARC Group

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.